IL-12 gene-modified bone marrow cell therapy suppresses the development of experimental metastatic prostate cancer.
IL-12 gene-modified bone marrow cell therapy suppresses the development of experimental metastatic prostate cancer. Cancer Gene Ther. 2007 Oct; 14(10):819-27.